Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- FGEN
- Price
- 9.22
- Stock movement down
- -0.28 (-2.95%)
- Company name
- FibroGen Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 37.30M
- Ent value
- 38.85M
- Price/Sales
- -
- Price/Book
- 2.13
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -23.09%
- Trailing P/E
- 0.17
- Forward P/E
- -
- PEG
- -
- EPS growth
- -53.64%
- 1 year return (CAGR)
- -40.94%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-12
DIVIDENDS
FGEN does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 0.17 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.13 |
| EV to Sales | -0.33 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.05M |
| EPS (TTM) | 53.33 |
| FCF per share (TTM) | -4.23 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -118.09M |
| Gross profit (TTM) | -97.71M |
| Operating income (TTM) | -124.04M |
| Net income (TTM) | 215.65M |
| EPS (TTM) | 53.33 |
| EPS (1y forward) | -11.95 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 82.74% |
| Operating margin (TTM) | 105.03% |
| Profit margin (TTM) | -182.61% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 117.97M |
| Net receivables | 121.00K |
| Total current assets | 133.42M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 137.01M |
| Accounts payable | 5.09M |
| Short/Current long term debt | 19.47M |
| Total current liabilities | 35.97M |
| Total liabilities | 119.53M |
| Shareholder's equity | 17.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.91M |
| Capital expenditures (TTM) | 179.00K |
| Free cash flow (TTM) | -17.09M |
| Dividends paid (TTM) | 3.95M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 1233.37% |
| Return on Assets | 157.40% |
| Return on Invested Capital | 1233.37% |
| Cash Return on Invested Capital | -97.75% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.51 |
| Daily high | 9.66 |
| Daily low | 9.22 |
| Daily Volume | 19K |
| All-time high | 1681.25 |
| 1y analyst estimate | 43.00 |
| Beta | 0.75 |
| EPS (TTM) | 53.33 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| FGEN | S&P500 | |
| Current price drop from All-time high | -99.45% | - |
| Highest price drop | -99.69% | -19.00% |
| Date of highest drop | 18 Jun 2025 | 8 Apr 2025 |
| Avg drop from high | -99.43% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 314 days | 89 days |
COMPANY DETAILS
Marketcap
37.30M
Marketcap category
Small-cap
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Employees
225
Website
Investor relations
-
SEC filings
CEO
Enrique A. Conterno
Country
USA
City
San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner